Dual GIP/GLP-1 Receptor Agonist
Physician review · Free delivery · Cancel anytime
SURMOUNT-1 Trial (2022) · 2,539 participants · 72 weeks
Average body weight reduction at 72 weeks. Bars scaled to 25% max. Individual results vary.
Zepbound (brand-name tirzepatide) demonstrated statistically significant, clinically meaningful weight loss vs. placebo in the SURMOUNT-1 trial. Participants followed a reduced-calorie diet and increased physical activity alongside treatment.
Important: The clinical trial data above refers to Zepbound, the FDA-approved brand-name tirzepatide. Compounded tirzepatide has not been studied in clinical trials and has not been approved by the U.S. Food and Drug Administration (FDA) for safety or efficacy. Compounded medications are prepared by licensed pharmacies under FDA oversight of pharmacy practices, but the compounded formulation itself is not FDA-approved.
Dual GIP + GLP-1 Receptor Agonist
Simultaneously activates both GIP and GLP-1 receptors — a dual-action mechanism not possible with GLP-1 agonists alone†
GIP receptor activation enhances fat metabolism and complements GLP-1's appetite-suppressing effects for greater total impact†
Slows gastric emptying and amplifies satiety signals, reducing caloric intake through two distinct hormonal pathways†
Head-to-head trial data shows superior weight loss compared to semaglutide at maximum doses†
†These statements have not been reviewed by the FDA.
Your clinician may adjust timing based on your individual response and tolerability.
Starter dose — gentle introduction to minimize GI side effects
Tolerance-building phase; appetite effects begin
Therapeutic range — meaningful weight loss typically begins here
Enhanced efficacy phase; most patients see significant progress
Advanced efficacy — approaching peak dose
Maximum dose — peak weight loss outcomes sustained
All dosages included in your monthly price. You will not be charged more as your dose increases through the titration schedule.
The standard titration schedule is designed to maximise weight loss in patients following a reduced-calorie diet. The microdosing protocol is a separate application — a single low dose held flat throughout treatment, calibrated for active individuals who want metabolic and recovery benefits without significant appetite suppression.
Flat weekly dose
1.25 mg/week
Dose comparison
Relative dose only. Not to clinical scale.
You pay the same from your first starter dose through maintenance. No surprise charges as your dose increases.
Complete a free intake. A licensed physician reviews your profile within 48 hours.
Start Tirzepatide Intake →No credit card required to start
